WellsSA, AsaSL, DralleH, et al.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid2015;25:567-610; doi: 10.1089/thy.2014.0335.
2.
WellsSA, PaciniF, RobinsonBG, SantoroM. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab2013;98(8):3149-3164; doi: 10.1210/jc.2013-1204.
3.
OnumaAE, SkefosCM, RichardsonME, et al.The shifting landscape of germline RET pathogenic variants with the introduction of panel testing. Surgery2026;189:109701; doi: 10.1016/j.surg.2025.109701.
4.
LovedayC, JosephsK, ChubbD, et al.p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer. J Clin Endocrinol Metab2018;103(11):4275-4282; doi: 10.1210/jc.2017-02529.
5.
EngC, ClaytonD, SchuffeneckerI, et al.The relationship between specific RET Proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA1996;276(19):1575-1579; doi: 10.1001/jama.1996.03540190047028.
6.
Frank-RaueK, RondotS, RaueF. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Mol Cell Endocrinol2010;322(1–2):2-7; doi: 10.1016/j.mce.2010.01.012.
7.
MachensA, DralleH. Therapeutic effectiveness of screening for multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab2015;100(7):2539-2545; doi: 10.1210/jc.2015-1689.
8.
HadouxJ, EliseiR, BroseMS, et al.Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med2023;389(20):1851-1861; doi: 10.1056/NEJMoa2309719.
9.
WhiteSL, JamilT, BellC, et al.Population prevalence of the major thyroid cancer–associated syndromes. J Clin Endocrinol Metab2025;110(12):e4049-e4054. doi: 10.1210/clinem/dgaf236.
